List view / Grid view


Synthetic biology is ready for the therapeutic limelight

22 September 2022 | By

After initially serving as a proving ground for integrating forward engineering principles into living cells, synthetic biology is making waves across diverse therapeutic areas. In this article, Dr Dan Mandell, Co-Founder and CEO of GRO Biosciences, explains how the field is reshaping our understanding of the limits of cell- and molecular-based medicines.

Advancing novel biotherapeutics based on synthetic biology

22 September 2022 | By

Researchers at Synlogic are clearing the path for a new class of medicine – biotherapeutics based on synthetic biology, called synthetic biotics, which are created by programming or engineering bacteria to metabolise or secrete well-validated targets of disease pathophysiology. In this article, Dr Caroline Kurtz, Chief Development Officer at Synlogic, discusses how synthetic…

In search of COVID-19 antibodies

22 September 2022 | By

Antibody therapy has been a critical part of the COVID-19 research campaign to treat severe cases. Unfortunately, despite many promising candidates, scientists have yet to find one that passes clinical trials. This article by Drug Target Review’s Ria Kakkad highlights some of the most recent developments in the search for COVID-19…

Drug Target Review Synthetic Biology ebook 2022

21 September 2022 | By

Within this ebook are features on synthetic biology, covering synthetic biotics and their potential to treat a wide range of diseases and conditions, while another piece examines the therapeutic directions the synthetic biology field will likely take in the future.

T-cell redirecting bispecific antibodies: the next era of immune-based therapies for multiple myeloma?

20 September 2022 | By

While the introduction of novel immunotherapies to combat and treat cancer has advanced patient care greatly, ever more effective solutions continue to be required. Here, Dr Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology at Janssen Europe, Middle East & Africa (EMEA), explores how T-cell redirecting bispecific antibodies (TRBAs)…

Drug Target Review Antibodies ebook 2022

14 September 2022 | By

In this ebook are articles on why monoclonal antibodies represent a high level of promise in the fight against cancer and how T-cell redirecting bispecific antibodies could work as a new immunotherapeutic strategy against haematological conditions. 

Drug Target Review – Issue 3 2022

14 September 2022 | By

In this issue are articles on synthetically engineered bacteria to deliver therapeutics, how single-molecule fluorescence resonance energy transfer was used to image GPCRs and a new assay to identify coronavirus drugs. Also included are pieces on vaccine development, monoclonal antibodies and neuroscience.

The potential of Ayurvedic medicine

21 July 2022 | By

In a recent study, scientists have highlighted the possible use of South Asian medicine, specifically, Ayurvedic medicine, to treat type 2 diabetes. In this article, Drug Target Review dives into the study’s implications and what it means for the western world of drug discovery.